200 related articles for article (PubMed ID: 29198959)
21. Circulating CD8
Lin KR; Pang DM; Jin YB; Hu Q; Pan YM; Cui JH; Chen XP; Lin YX; Mao XF; Duan HB; Luo W
Cancer Immunol Immunother; 2018 Nov; 67(11):1743-1752. PubMed ID: 30167861
[TBL] [Abstract][Full Text] [Related]
22. Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy.
Park JH; Jang M; Tarhan YE; Katagiri T; Sasa M; Miyoshi Y; Kalari KR; Suman VJ; Weinshilboum R; Wang L; Boughey JC; Goetz MP; Nakamura Y
Int J Oncol; 2016 Aug; 49(2):471-8. PubMed ID: 27278091
[TBL] [Abstract][Full Text] [Related]
23. IFI30 as a key regulator of PDL1 immunotherapy prognosis in breast cancer.
Li L; Fei Y; Dong T; Song Y; Chen X; Zhang H; Zhou H; Liang M; Tang J
Int Immunopharmacol; 2024 May; 133():112093. PubMed ID: 38669947
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy is linked to an amended anti-tumorigenic microenvironment in gastric cancer.
Huan X; Zou K; Zhang P; Ding H; Luo C; Xiang C; Xu S; Zhuang Y; Wu C; Wang Y; Wu X; Chen C; Zhang J; Yao X; Liu F; Liu S; Wu Z
Int Immunopharmacol; 2024 Jan; 127():111352. PubMed ID: 38091833
[TBL] [Abstract][Full Text] [Related]
25. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
[TBL] [Abstract][Full Text] [Related]
26. Investigating Radiotherapy Effects on PD-L1 Expression in Circulating Tumor Cells: An Exploratory Study.
Rafli R; Harahap WA; Gondhowiardjo S; Ekaputra A
Asian Pac J Cancer Prev; 2024 May; 25(5):1559-1566. PubMed ID: 38809627
[TBL] [Abstract][Full Text] [Related]
27. Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
Fukui R; Watanabe T; Morimoto K; Fujimoto Y; Nagahashi M; Ishikawa E; Hirota S; Miyoshi Y
Breast Cancer; 2024 May; 31(3):536-538. PubMed ID: 38433180
[No Abstract] [Full Text] [Related]
28. Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study.
Ayoub NM; Fares M; Marji R; Al Bashir SM; Yaghan RJ
Breast Cancer (Dove Med Press); 2021; 13():603-615. PubMed ID: 34803400
[TBL] [Abstract][Full Text] [Related]
29. TWIST1 Drives Cytotoxic CD8+ T-Cell Exhaustion through Transcriptional Activation of
Yu X; Xu J
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893094
[TBL] [Abstract][Full Text] [Related]
30. Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells.
Hühn D; Martí-Rodrigo P; Mouron S; Hansel C; Tschapalda K; Porebski B; Häggblad M; Lidemalm L; Quintela-Fandino M; Carreras-Puigvert J; Fernandez-Capetillo O
Mol Oncol; 2022 Jan; 16(1):148-165. PubMed ID: 34392603
[TBL] [Abstract][Full Text] [Related]
31. The role of immune infiltrates as prognostic biomarkers in patients with breast cancer.
Baxevanis CN; Sofopoulos M; Fortis SP; Perez SA
Cancer Immunol Immunother; 2019 Oct; 68(10):1671-1680. PubMed ID: 30905043
[TBL] [Abstract][Full Text] [Related]
32. Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models.
Bender LH; Abbate F; Walters IB
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599852
[TBL] [Abstract][Full Text] [Related]
33. Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models.
Padmanabhan R; Kheraldine HS; Meskin N; Vranic S; Al Moustafa AE
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32164163
[TBL] [Abstract][Full Text] [Related]
34. CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer.
Huang H; Yao Y; Shen L; Jiang J; Zhang T; Xiong J; Li J; Sun S; Zheng S; Jia F; Zhou J; Yu X; Chen W; Shen J; Xia W; Shao X; Wang Q; Huang J; Ni C
Clin Cancer Res; 2023 Dec; 29(24):5227-5243. PubMed ID: 37831062
[TBL] [Abstract][Full Text] [Related]
35. HER2 and PD-L1 Expression in Gastric and Gastroesophageal Junction Cancer: Insights for Combinatorial Targeting Approaches.
Freitas MB; Gullo I; Leitão D; Águas L; Oliveira C; Polónia A; Gomes J; Carneiro F; Reis CA; Duarte HO
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539559
[TBL] [Abstract][Full Text] [Related]
36. Multiplex three-dimensional optical mapping of tumor immune microenvironment.
Lee SS; Bindokas VP; Kron SJ
Sci Rep; 2017 Dec; 7(1):17031. PubMed ID: 29208908
[TBL] [Abstract][Full Text] [Related]
37. Exploration of immune checkpoint inhibitors in neoadjuvant therapy of early-stage breast cancer.
Ren TY; Bi Z
Int J Surg; 2024 Apr; 110(4):2479-2480. PubMed ID: 38241339
[No Abstract] [Full Text] [Related]
38. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
Hou Y; Nitta H; Wei L; Banks PM; Lustberg M; Wesolowski R; Ramaswamy B; Parwani AV; Li Z
Breast J; 2018 Nov; 24(6):911-919. PubMed ID: 30230111
[TBL] [Abstract][Full Text] [Related]
39. Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.
Force J; Howie LJ; Abbott SE; Bentley R; Marcom PK; Kimmick G; Westbrook K; Sammons SL; Parks M; Topping DL; Emerson R; Broadwater G; Hyslop T; Blackwell KL; Nair SK
Clin Breast Cancer; 2018 Oct; 18(5):410-417. PubMed ID: 29615305
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
Sci Rep; 2019 Nov; 9(1):16662. PubMed ID: 31723167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
